These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34857545)

  • 1. SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
    Boeder SC; Gregory JM; Giovannetti ER; Pettus JH
    Diabetes; 2022 Mar; 71(3):511-519. PubMed ID: 34857545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
    Boeder S; Edelman SV
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients.
    Rickels MR; Schutta MH; Mueller R; Kapoor S; Markmann JF; Naji A; Teff KL
    J Clin Endocrinol Metab; 2007 Mar; 92(3):873-9. PubMed ID: 17192287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes.
    Galassetti P; Tate D; Neill RA; Morrey S; Wasserman DH; Davis SN
    Diabetes; 2003 Jul; 52(7):1761-9. PubMed ID: 12829644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.
    Alsalim W; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Jul; 20(7):1652-1658. PubMed ID: 29498469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A; Solis-Herrera C; Daniele G; Eldor R; Fiorentino TV; Tripathy D; Xiong J; Perez Z; Norton L; Abdul-Ghani MA; DeFronzo RA
    J Clin Invest; 2014 Feb; 124(2):509-14. PubMed ID: 24463448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antecedent hypoglycemia on cognitive function and on glycemic thresholds for counterregulatory hormone secretion in healthy humans.
    Mellman MJ; Davis MR; Brisman M; Shamoon H
    Diabetes Care; 1994 Mar; 17(3):183-8. PubMed ID: 8174445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
    Lundkvist P; Pereira MJ; Kamble PG; Katsogiannos P; Langkilde AM; Esterline R; Johnsson E; Eriksson JW
    J Clin Endocrinol Metab; 2019 Jan; 104(1):193-201. PubMed ID: 30137410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin.
    Tsui EY; Chiasson JL; Tildesley H; Barnie A; Simkins S; Strack T; Zinman B
    Diabetes Care; 1998 Jan; 21(1):93-6. PubMed ID: 9538976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
    van Meijel LA; Tack CJ; de Galan BE
    Diabetes Obes Metab; 2021 Nov; 23(11):2582-2589. PubMed ID: 34338413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
    Akturk HK; Rewers A; Garg SK
    Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):246-250. PubMed ID: 29794497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
    Kurozumi A; Okada Y; Tanaka Y
    Endocr J; 2021 Mar; 68(3):361-369. PubMed ID: 33208570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.